Emerging immunotherapy in advanced renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 12, 2017, Pages 687-693

  Mendiratta, Prateek ^a   Rini, Brian I ^a   Ornstein, Moshe C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Checkpoint inhibitors; Immunotherapy; Kidney cancer; Renal cell carcinoma; Targeted therapy

Indexed keywords

CANCER VACCINE; CHECKPOINT KINASE INHIBITOR; INTERFERON; INTERLEUKIN 2; NIVOLUMAB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CELL CARCINOMA; REVIEW; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85035797451     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2017.08.011     Document Type: Review

References (60)

1. Rini, B.I., Vogelzang, N.J., Dumas, M.C., Wade, J.L. 3rd, Taber, D.A., Stadler, W.M., Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18 (2000), 2419–2426.
2. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353 (1999), 14–17.
3. Fisher, R.I., Rosenberg, S.A., Fyfe, G., Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:Suppl. 1 (2000), S55–S57.
4. Choueiri, T.K., Motzer, R.J., Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 376 (2017), 354–366.
5. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
6. McDermott, D.F., Regan, M.M., Clark, J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005), 133–141.
7. Belldegrun, A.S., Klatte, T., Shuch, B., et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989–2005): a benchmark for emerging targeted cancer therapies. Cancer 113 (2008), 2457–2463.
8. Rini, B.I., McDermott, D.F., Hammers, H., et al. Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer, 4, 2016, 81.
9. Atkins, M.B., Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 26:Suppl. 1 (2009), 18–22.
10. McDermott, D.F., Cheng, S.-C., Signoretti, S., et al. The high-dose aldesleukin “Select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res, 21, 2015, 561.
11. Clark, J.I., Wong, M.K.K., Kaufman, H.L., et al. Impact of sequencing targeted therapies with high-dose interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial: PROCLAIMSM. Clin Genitourin Cancer, 15, 2017 31–41.e4.
12. Minasian, L.M., Motzer, R.J., Gluck, L., Mazumdar, M., Vlamis, V., Krown, S.E., Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11 (1993), 1368–1375.
13. Rini, B.I., Halabi, S., Rosenberg, J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008), 5422–5428.
14. Escudier, B.J., Bellmunt, J., Negrier, S., et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol, 27, 2009, 5020.
15. Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
16. Chambers, C.A., Sullivan, T.J., Allison, J.P., Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7 (1997), 885–895.
17. Balar, A.V., Weber, J.S., PD-1. and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66 (2017), 551–564.
18. Motzer, R.J., Rini, B.I., McDermott, D.F., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33 (2015), 1430–1437.
19. Harris, S.J., Brown, J., Lopez, J., Yap, T.A., Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 13 (2016), 171–193.
20. Cella, D., Grunwald, V., Nathan, P., et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 17 (2016), 994–1003.
21. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
22. Curran, M.A., Montalvo, W., Yagita, H., Allison, J.P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107 (2010), 4275–4280.
23. Hammers, H.J., Plimack, E.R., Infante, J.R., et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol, 2017 JCO2016721985.
24. Lara, P., Bauer, T.M., Hamid, O., et al. Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I/II results from ECHO-202/KEYNOTE-037. J Clin Oncol, 35, 2017, 4515.
25. Fong, L., Forde, P.M., Powderly, J.D., et al. Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. J Clin Oncol, 35, 2017, 3004.
26. Sanborn, R.E., Pishvaian, M.J., Kluger, H.M., et al. Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients. J Clin Oncol, 35, 2017, 3007.
27. Liu, X.D., Hoang, A., Zhou, L., et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3 (2015), 1017–1029.
28. Ko, J.S., Zea, A.H., Rini, B.I., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15 (2009), 2148–2157.
29. Gabrilovich, D.I., Chen, H.L., Girgis, K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996), 1096–1103.
30. Chowdhury, S., McDermott, D.F., Voss, M.H., et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol, 35, 2017, 4506.
31. McDermott, D.F., Atkins, M.B., Motzer, R.J., et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol, 35, 2017, 431.
32. Mcdermott D, Huseni, M, Rini, B, et al. Molecular correlates of differential response to atezolizumab ± bevacizumab vs sunitnib in a phase II study in untreated metastatic renal cell carcinoma (RCC) patients. AACR Annual Meeting, Washington, DC; April 3, 2017.
33. Atkins, M.B., Plimack, E.R., Puzanov, I., et al. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): preliminary safety and efficacy results. Ann Oncol 27 (2016), 266–295.
34. Choueiri, T.K., Rini, B.I., Larkin, J.M.G., et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). J Clin Oncol, 35, 2017 TPS4594-TPS.
35. Pal, S.K., Hu, A., Figlin, R.A., A new age for vaccine therapy in renal cell carcinoma. Cancer J 19 (2013), 365–370.
36. Hirbod-Mobarakeh, A., Gordan, H.A., Zahiri, Z., et al. Specific immunotherapy in renal cancer: a systematic review. Ther Adv Urol 9 (2017), 45–58.
37. Kirner, A., Mayer-Mokler, A., Reinhardt, C., IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother 10 (2014), 3179–3189.
38. Walter, S., Weinschenk, T., Stenzl, A., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18 (2012), 1254–1261.
39. Finke, J.H., Rini, B., Ireland, J., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14 (2008), 6674–6682.
40. Rini, B.I., Stenzl, A., Zdrojowy, R., et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17 (2016), 1599–1611.
41. Amin, A., Dudek, A.Z., Logan, T.F., et al. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer, 3, 2015, 14.
42. Dendritic Immunotherapy Falters in Phase III RCC Trial Onclive. http://www.onclive.com/web-exclusives/dendritic-immunotherapy-falters-in-phase-iii-rcc-trial; 2017 [Accessed June 17, 2017].
43. Choueiri, T.K., Fay, A.P., Gray, K.P., et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25 (2014), 2178–2184.
44. Choueiri, T.K., Figueroa, D.J., Fay, A.P., et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 21 (2015), 1071–1077.
45. Leite, K.R., Reis, S.T., Junior, J.P., et al. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol, 10, 2015, 189.
46. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
47. Naidoo, J., Page, D.B., Li, B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol, 27, 2016, 1362.
48. Michot, J.M., Bigenwald, C., Champiat, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
49. Weber, J.S., Dummer, R., de Pril, V., Lebbé C., Hodi, F.S., for the MDXI. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer 119 (2013), 1675–1682.
50. Nishino, M., Sholl, L.M., Hatabu, H., Ramaiya, N.H., Hodi, F.S., Anti–PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373 (2015), 288–290.
51. Champiat, S., Lambotte, O., Barreau, E., et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27 (2016), 559–574.
52. McDermott, D.F., Drake, C.G., Sznol, M., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33 (2015), 2013–2020.
53. de Velasco, G., Krajewski, K.M., Albiges, L., et al. Radiologic heterogeneity in responses to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. Cancer Immunol Res 4 (2016), 12–17.
54. Hodi, F.S., Hwu, W.J., Kefford, R., et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34 (2016), 1510–1517.
55. Escudier, B., Motzer, R.J., Sharma, P., et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol 72 (2017), 368–376.
56. George, S., Motzer, R.J., Hammers, H.J., et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2 (2016), 1179–1186.
57. Wolchok, J.D., Hoos, A., Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res, 15, 2009, 7412.
58. McDermott, D.F., Sosman, J.A., Sznol, M., et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34 (2016), 833–842.
59. Koshkin, V.S., Barata, P.C., Vogelzang, N.J., et al. Nivolumab treatment for patients with non-clear cell renal cell carcinoma: a multicenter retrospective analysis. J Clin Oncol, 35, 2017, 4586.
60. Moreira, R.B., McKay, R.R., Xie, W., et al. Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol, 35, 2017, 482.